

# ECOSOC

Special Event on Philanthropy  
and the Public Health Agenda  
February 23, 2009




Raising the profile of the  
neglected tropical diseases


Bernard Pécoul, MD/MPH  
Executive Director, DNDi



glected




# Neglected Diseases: Current Treatment Limitations



- Ineffective (resistance)
- Toxic
- Expensive
- Painful when delivered
- Difficult to use
- Not registered in endemic regions
- Restricted by patents

# DNDi's Virtual Model Attracting Partnerships across the Globe

# A robust portfolio to deliver 6-8 treatments by 2014



# 3 Products already available

2007

**ASAQ** (Malaria)  
Fixed-Dose  
Artesunate/  
Amodiaquine



Partners

**sanofi-aventis**  
(France)

2008

**ASMO**



**Farmanguinhos**  
(Brazil)

- Easy to Use
- Affordable
-

## Funding Diversity

**\$150M of \$350M. Secured (2004 -2014)**



## Ensuring Sustainability Via Public Leadership & Private Contributions

- Establish agenda and R&D priorities  
(implementation of WHO's Global Action Plan)
- Significantly invest with sustainable funding
- Access to knowledge and new science for R&D
- Allow rapid approval & delivery and devise new  
IP management policies to encourage  
needs-driven R&D
- Transfer technology and strengthen research  
capacities in developing countries



By working in a creative way,  
we can bring together innovation  
to neglected patients!



[www.dndi.org](http://www.dndi.org)

